Shaanxi Meibang Pharmaceutical Group Co., Ltd.
605033.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | CN¥1,642,285 | CN¥2,402,670 | CN¥2,314,624 | CN¥3,611,192 |
| - Cash | CN¥267,863 | CN¥481,172 | CN¥318,247 | CN¥254,388 |
| + Debt | CN¥72,000 | CN¥1,001 | CN¥105,567 | CN¥27,051 |
| Enterprise Value | CN¥1,446,422 | CN¥1,922,499 | CN¥2,101,944 | CN¥3,383,855 |
| Revenue | CN¥885,528 | CN¥699,027 | CN¥906,046 | CN¥842,490 |
| % Growth | 26.7% | -22.8% | 7.5% | – |
| Gross Profit | CN¥252,787 | CN¥220,987 | CN¥377,230 | CN¥322,428 |
| % Margin | 28.5% | 31.6% | 41.6% | 38.3% |
| EBITDA | CN¥59,615 | CN¥84,134 | CN¥168,820 | CN¥154,616 |
| % Margin | 6.7% | 12% | 18.6% | 18.4% |
| Net Income | CN¥36,859 | CN¥57,557 | CN¥145,088 | CN¥125,743 |
| % Margin | 4.2% | 8.2% | 16% | 14.9% |
| EPS Diluted | 0.27 | 0.43 | 1.07 | 1.14 |
| % Growth | -37.2% | -59.8% | -6.1% | – |
| Operating Cash Flow | CN¥280,399 | CN¥334,789 | CN¥126,412 | -CN¥108,754 |
| Capital Expenditures | -CN¥158,812 | -CN¥203,690 | -CN¥109,290 | -CN¥106,528 |
| Free Cash Flow | CN¥121,587 | CN¥131,099 | CN¥17,122 | -CN¥215,282 |